Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Arthritis Research & Therapy

Figure 4

From: Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

Figure 4

The effect of 25 mg/kg apremilast or rolipram on spontaneous behaviour was tested on naïve mice using LABORAS automated activity monitor. The average time spent (a) immobile and grooming and (b) climbing and during locomotion are plotted. n = 8 per group, * P < 0.05, *** P < 0.001, relative to vehicle treatment. Mice were monitored for 30 minutes, one hour after receiving treatment. n.s., not significant.

Back to article page